[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"resectable-pancreatic-ductal-adenocarcinoma-pdac\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:resectable-pancreatic-ductal-adenocarcinoma-pdac":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":55},"100612334","phase-3-study-of-daraxonrasib-rmc-6236-in-patients-with-resected-pancreatic-ductal-adenocarcinoma-pdac-100612334",false,"NCT07252232","Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)","RASolute 304: A Phase 3 Multicenter, Open-label, Randomized, 2-Arm Study of Adjuvant Daraxonrasib Versus Standard of Care Observation Following Completion of Neoadjuvant and\u002For Adjuvant Chemotherapy in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)","RASolute 304","Inclusion Criteria:\n\n* At least 18 years old and has provided informed consent.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Histologically confirmed PDAC with successful (R0\u002FR1) curative intent surgical resection and no evidence of recurrent or metastatic disease.\n* Must have received perioperative (neoadjuvant, adjuvant, or a combination of both) multi-agent chemotherapy.\n* Must have completed most recent treatment within the past 12 weeks.\n* Adequate organ function (bone marrow, liver, kidney, coagulation).\n* Documented RAS mutation status.\n* Able to take oral medications.\n\nExclusion Criteria:\n\n* Prior therapy with direct RAS-targeted therapy (eg. degraders and\u002For inhibitors).\n* Any conditions that may affect the ability to take or absorb study drug.\n* Major surgery within 28 days prior to randomization.\n* Patient is unable or unwilling to comply with protocol-required study visits or procedures.","ALL","18 Years",{"count":20,"type":21},500,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard of care (SOC) observation only.",[27,28,29,30,31],"Pancreatic Cancer","PDAC","PDAC - Pancreatic Ductal Adenocarcinoma","Resectable Pancreatic Ductal Adenocarcinoma (PDAC)","Resected Pancreatic Adenocarcinoma",[27,28,33,34,35,36,37,38,39,40,41,31,42],"Pancreatic Ductal Adenocarcinoma","RAS","KRAS","NRAS","HRAS","RAS Wild-Type","RASolute","Resectable Pancreatic Ductal Adenocarcinoma","Resectable PDAC","RAS Mutation","RECRUITING","2026-06-17",{"date":46,"type":47},"2026-06-22","ACTUAL",{"date":49,"type":47},"2025-12-15",{"date":51,"type":21},"2030-07-10",{"name":53,"class":54},"Revolution Medicines, Inc.","INDUSTRY",34]